Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 839–840 (1 August 2008) | doi:10.1038/nbt0808-839
EGFR inhibitors embrace KRAS
Abstract
A single-gene test is reshaping the lung and bowel cancer space by offering to tailor treatment to the genetic profile of a tumor. The presence of a KRAS mutation, which can identify those individuals best treated with epidermal growth factor receptor (EGFR) inhibitors, provides welcome clarity to clinicians.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
